Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-01-09
2007-01-09
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S015800, C530S300000, C530S324000, C530S325000, C530S326000, C530S327000, C530S334000, C530S344000, C435S069100, C424S009100
Reexamination Certificate
active
11042492
ABSTRACT:
Peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing at least one of an integrin binding motif such as an RGD sequence, a glycosaminoglycan binding motif, and a calcium binding motif, and the remainder of amino acids contiguous with the RGD sequence in matrix extracellular phosphoglycoprotein. The sequences may be formulated for injection or dispersed in toothpaste or a mouthwash or gum patch and administered to enhance bone/tooth growth and/or reduce excessive urinary phosphate loss from the body.
REFERENCES:
patent: 5015628 (1991-05-01), Reynolds
patent: 5407644 (1995-04-01), Rytter et al.
patent: 5837674 (1998-11-01), Kumagai et al.
patent: 5849865 (1998-12-01), Cheng et al.
patent: 6027592 (2000-02-01), Tseng et al.
patent: 6045780 (2000-04-01), Bixler et al.
patent: 6146655 (2000-11-01), Ruben
patent: 6300062 (2001-10-01), Cerny et al.
patent: 6329357 (2001-12-01), Norman et al.
patent: 6673900 (2004-01-01), Rowe
patent: 6790639 (2004-09-01), Brown et al.
patent: 6911425 (2005-06-01), Kumagai et al.
patent: 2002/0102641 (2002-08-01), Schia et al.
patent: 2002/0197267 (2002-12-01), Kumagai et al.
patent: 2003/0166239 (2003-09-01), Brown et al.
patent: WO 95/14714 (1995-06-01), None
patent: WO 99/08730 (1999-02-01), None
patent: WO 99/48909 (1999-02-01), None
patent: WO 99/43844 (1999-09-01), None
patent: WO 99/48909 (1999-09-01), None
patent: WO 99/60017 (1999-11-01), None
patent: WO 00/52041 (2000-09-01), None
patent: WO 01/72826 (2001-10-01), None
patent: WO 02/05836 (2002-01-01), None
Bairoch et al. (1990) “EF-hand motifs in inositol phospholipid-specific phospholipase C.”FEBS, vol. 269(2):454-456.
Chappard et al., (1995) “Effects of tiludronate on bone loss in paraplegic patients,”Journal of Bone and Mineral Research, 10(1):112-118.
Chauvaux et al. (1990) “Calcium-binding affinity and calcium-enhanced activity of Clostridium thermocellum endoglucanase D.”Biochem. J.,vol. 265:261-265.
Davis (1990) “The many Faces of Epidermal Growth Factor Repeats.”The New Biologist,vol. 2(5):410-419.
Economou et al. (1990) “The Rhizobium nodulation gene nodO encodes a Ca2+-binding protein that is exported without N-terminal cleavage and is homologous to haemolysin and related proteins.”The EMBO Journal,vol. 9(2):349-354.
Ferris D. M. et al., “RGD-coated titanium implants stimulate increased bone formation in vivo” Biomaterials, Vo. 20, No. 23-24, Dec. 1999. pp. 2323-2331.
Fratzl et al., (1994) “Abnormal bone mineralization after fluoride treatment in osteoporosis: a small-angle x-ray-scattering study.”Journal of Bone and Mineral Research,9(10):1541-1549.
Gennari et al., (1994) “Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment,”Drug Saf.,11(3):179-95.
Gronowicz et al., (1994) “Synthetic peptide containing Arg-Gly-Asp inhibits bone formation and resorption in a mineralizing organ culture system of fetal rat parietal bones.”Journal of Bone and Mineral Research,9(2):193-201.
Hayashibara T. et al., “A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo” Journal of Bone and Mineral Research, New York, NY., US, vol. 19, No. 3, Mar. 2004, pp. 455-462.
Hilfiker, (1998) “Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine,”Proc. Natl. Acad. Sci. USA,95(24):14564-14569.
Kawasaki et al. (1995) “Calcium-Binding Proteins 1: EF-hands.”Protein Profile,vol. 2(4):305-356.
Lopez-Moratalla et al., “A common structural motif in immunopotentiating peptides with sequences present in human autoantigens. Elicitation of a response mediated by monocytes and Th1 cells” Biochimica et Biophysica Acta, vol. 1317, No. 3, 1996, pp. 183-191.
Lufkin et al., (1994) “Pamidronate: an unrecognized problem in gastrointestinal tolerability,”Osteoporos. Int.,4(6):320-322.
Moncrief et al. (1990) “Evolution of EF-Hand Calcium-Modulated Proteins. I. Relationships Based on Amino Acid Sequences,”J. Mol. Evol.,vol. 30:522-562.
Mundy et al., (1999) “Stimulation of bone formation in vitro and in rodents by statins.”Science,286:1946-1949.
Rowe et al., (2000) “MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia,”Genomics,67:54-68.
Schafer et al. (1995) “Isolation of a YAC Clone Covering a Cluster of Nine S100 Genes on Human Chromosome 1q21: Rationale for a New Nomenclature of the S100 Calcium-Binding Protein Family.”Genomics,vol. 25:638-643.
Schneider et al., (1995) “Does HRT modify risk of gynecological cancers?”Int. J. Fertil. Menopausal Study,40(1):40-53.
Springer et al. (2000) “A Novel Ca2+Binding β Hairpin Loop Better Resembles Integrin Sequence Motifs than the EF Hand,”Cell,vol. 102:275-377.
Traianedes et al., (1998) “5-Lipoxygenase metabolites inhibit bone formation in vitro.”Endocrinology,139:3178-3184.
Yang et al., “Peptide analogs from E-cadherin with different calcium-binding affinities”J. Peptide Res.55:203-215 (2000).
Abe et al., “Differentiation of mouse myeloid leukemia cells induced by 1α,25-dihydroxyvitamine D3”PNAS, 78(8):4990-4994 (1981).
Bikle, “Vitamin D: New Actions, New Analogs, New Therapeutic Potential; Update 1995”Endocrine Review, 4(1):77-83 (1995).
Brenza et al., “Parathyroid hormone activation of the 25-hydroxyvitamine D3-1α-Hydroxylase gene promoter”PNAS95:1387-1391 (1998).
Carpenter, “New Perspectives on the Biology and Treatment of X-Linked Hypophsphatemic Rickets”Pediatric endocrinology44(2):443-465 (1997).
Carswell, “The Potential for Treating Neurodegenerative Disorders with NGF-Inducing Compounds”Experimental Neurology, 124:36-42 (1993).
Ecarot et al., “Defective Bone Formation by Hyp Mouse Bone Cells Trasplanted into Normal Mice: Evidence in Favor of an Intrinsic Osteobiast Defect”Journal of Bone and Mineral Research, 7:215-200 (1992).
Ecarot et al., “Effect of 1,25-Dihydroxyvitamin D3 Treatment on Bone Formation by Transplanted Cells from Normal and X-linked Hypophosphatemic Mice”Journal of Bone and Mineral Research, 10:424-431 (1995).
Eto et al., “Assay of 25-Hydroxyvitamin D3 1 α-Hydroxylase in Rat Kidney Mitochondria”Analytical Biochemistry, 258:53-58 (1998).
Fisher et al., “Inhibition of Osteoclastic Bone Resorption In Vivo by Eschistatin an ‘Arglnyol-Glycyl-Aspartyl’ (RGD)-Containing Protein”Endocrinology, 132(3):1411-1413 (1993).
George et al., “Characterization of a Novel Dentin Matrix Acidic Phosphoprotein”The Journal of Biological Chemistry, 268(17):12624-12630 (1993).
Hewison et al., “1α-Hydroxylase and the action of vitamin D”Journal of Molecular Endocrinology, 25:141-148 (2000).
Horton et al., “Arg-Gly-Asp (RGD) Peptides and the Anti-Vitronectin Receptor Antibody 23C6 Inhibit Denline Resorption and Cell Spreading by Osteoclasts”Experimental Cell Research, 195:368-375 (1991).
Inomata et al., “Effect of 1α(OH)-vitamin D3 on insulin secretion in diabetes mellitus”Bone and Mineral, 1:187-192 (1986).
Kato et al., “Molecular Genetics of Vitamin D-Dependent Hereditary Rickets”Hormone Research, 57:73-78 (2002).
Kimmel-Jehan et al., “Cloning of the mouse 25-hydroxyvitamin D3-1α-hydroxylase (CYP1α) gene”Biochimica et Biophysica Acta, 1475:109-113 (2000).
Lajeunesse et al., “Direct demonstration of a humorally-mediated inhibition of renal phosphate transport in the Hyp mouse”Kidney Interntional50:1531-1538 (1996).
Martin et al., “Strategies to Minimize Bone Disease in Renal Fallure”American Journal of Kidney Diseases, 38(6):1430-1436 (2001).
Meyer et al., “The Renal P
Blacher Russell Wayne
Kumagai Yoshinari
Nomizu Motoyoshi
Yoneda Toshiyuki
Acologix, Inc.
Bozicevic Karl
Bozicevic Field & Francis LLP
Kam Chih-Min
LandOfFree
Integrin binding motif containing peptides and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin binding motif containing peptides and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin binding motif containing peptides and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3751517